Predicted Trait | |
Reported Trait | Lipoprotein (a) |
Mapped Trait(s) | lipoprotein A measurement (EFO_0006925) |
Score Construction | |
PGS Name | LPA_PRS |
Development Method | |
Name | Genome-wide significant SNPs |
Parameters | p<5E-08 |
Variants | |
Original Genome Build | NR |
Number of Variants | 36 |
Effect Weight Type | beta |
PGS Source | |
PGS Catalog Publication (PGP) ID | PGP000766 |
Citation (link to publication) | Türkmen D et al. Pharmacogenomics J (2024) |
Ancestry Distribution | |
Source of Variant Associations (GWAS) | European: 100% 20,793 individuals (100%) |
PGS Evaluation | European: 100% 1 Sample Sets |
Study Identifiers | Sample Numbers | Sample Ancestry | Cohort(s) |
---|---|---|---|
Europe PMC: 29926099 |
20,793 individuals | European | CCHS, CGPS, EPIC, PROSPER, WOSCOPS |
PGS Performance Metric ID (PPM) |
PGS Sample Set ID (PSS) |
Performance Source | Trait |
PGS Effect Sizes (per SD change) |
Classification Metrics | Other Metrics | Covariates Included in the Model |
PGS Performance: Other Relevant Information |
---|---|---|---|---|---|---|---|---|
PPM023061 | PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Incident heart failure | HR: 1.09 [1.04, 1.14] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
PPM023062 | PSS012106| European Ancestry| 32,360 individuals |
PGP000766 | Türkmen D et al. Pharmacogenomics J (2024) |
Reported Trait: Coronary heart disease | HR: 1.11 [1.08, 1.14] | — | — | sex, age at first prescription and genetic principal components 1 to 10 | — |
PGS Sample Set ID (PSS) |
Phenotype Definitions and Methods | Participant Follow-up Time | Sample Numbers | Age of Study Participants | Sample Ancestry | Additional Ancestry Description | Cohort(s) | Additional Sample/Cohort Information |
---|---|---|---|---|---|---|---|---|
PSS012106 | — | — | 32,360 individuals, 54.4 % Male samples |
— | European | — | UKB | — |